Red, White and Budget Cuts
How politics are tied to biomedical research
By CARMEN MARTI
For virtually his entire administration, President George W.
Bush has financed his decision to invade Iraq and fight in Afghanistan,
while generating the largest defense budget since World War II. Since
coming to office, the administration has increased baseline military
spending by 30 percent, to $515.4 billion. The national defense budget
rose 10 percent this year alone.
To accommodate these increases, other budgets have been cut. For
example, spending has declined for the justice department, public
housing programs, the U.S. Forest Service, literacy initiatives, the
Environmental Protection Agency and biomedical research.
While each of these line items would argue its function in the
country is requisite to American values, perhaps none would be more
entitled to claim its importance for humanity than biomedical research.
It’s this work that leads to treatments and cures for health conditions
and diseases, arguably saving more lives and lending more to quality of
life than any other endeavor. As medical watchdog and blogger Randall
Parker put it, “Biomedical research funding will deliver more benefit
per dollar spent than any other form of government spending.”
The 2007 budget proposed what is in real dollars the first cut in
spending at the National Institutes of Health in its history. According
to an American Association for the Advancement of Science report on the
Fiscal Year 2008 NIH budget, funding will fall $329 million or 1.1
percent to $28.8 billion in 2008 from the recently finalized 2007
budget. With a budget of nearly $30 billion, the NIH is the largest
government funder of biomedical research. The Centers for Disease
Control and Prevention (CDC) and National Science Foundation have
budgets of approximately $5 billion.
The report went on to say that under the current proposal, the “NIH
would continue to fall well behind its own calculations of biomedical
research inflation, estimated at 3.7 percent both this year and 2008.
The NIH budget would fall 12 percent from 2004 to 2008 based on these
calculations, and 8 percent based on economy-wide inflation.”
Was this bound to happen? For years under President Bill Clinton,
the NIH enjoyed 14- to 15-percent budget increases. In 1998, Clinton
proposed a $1 billion boost for the National Institutes of Health. He
and Congress talked of doubling the agency’s budget in five years.
And they almost did it. Between 1999 and 2003, the budget went from
$15 billion to $26.4 billion. But since 2004, annual increases have
hovered around 2 percent. This marks the fifth consecutive year the NIH
budget failed to keep up with the rate of inflation in the cost of
conducting biomedical research. Funding for NIH increased by 1.1
percent whereas the cost of conducting research is estimated to
increase between 5 and 6 percent every year.
Some argue the correction was necessary. In a 2006 editorial in the
journal, Medical Hypotheses, British researcher Bruce G. Charlton,
argued, “As funding increases, diminishing returns will set-in,
opportunity costs will begin to bite, and there will be more and more
social benefit to be gained from spending the extra research money on
something else.” He suggested that after a short term “quantitative
decline of research production,” a more efficient medical research
system will emerge. “Perhaps,” Charlton wrote, “a renaissance of
medical research lies not too many years in the future.”
But others say a loss of research production will hurt U.S. standing
as the world leader in biomedical advances. In an August 2001 speech,
Bush applauded the, “long and proud record of leading the world toward
advances in science and medicine that improve human life.” Yet, critics
such as Mary Woolley, president and CEO of Research!America, an
advocacy group funded by many organizations and the pharmaceutical
industry, say this is the legacy that spending cuts threaten. “Sadly,”
she said in a statement about current funding, “the White House no
longer seems to view such spending as a priority. Today, the National
Institutes of Health is only able to fund two in 10 qualified medical
research projects. The president’s 2009 budget recommendation could
slow this rate even further—proposing no increase for the NIH and
budget cuts for the Centers for Disease Control and Prevention and
other health agencies.”
Increasingly, scientists decry the slump in federal research funding
as a setback for medical progress, saying it jeopardizes the country’s
dominance in science, just as competition in Europe and China is
growing.
“We’re mortgaging our future by not funding this research now,” said
Nobel laureate, Thomas Cech, president of the Howard Hughes Medical
Institute. Cech was referring to the recommendations of a new study he
chaired by the American Academy of Arts and Sciences. In order to
preserve U.S. leadership in science and technology, the June 2008 White
Paper says there must be targeted programs and policies to support
early-career investigators and high-risk, high-reward research.
The report, “ARISE: Advancing Research In Science and Engineering,”
went on to say that its committee, “decided not to distract from its
message about modes of funding by tackling budgetary issues.”
That’s the problem, according to Dr. Herbert Sohn, medical facility
entrepreneur and attending urologist at Weiss Memorial Hospital in
Chicago. Sohn, who is also an attorney, has been active in medical
politics for decades, with several runs for Congress in the 1980s and
90s. Today he sits on numerous committees, including the Wye River
Group on Healthcare, a 20-year-old nonpartisan, nonprofit organization
to promote healthcare reform, and the Institute for Truth in
Accounting, an organization striving for increased credibility in
financial reporting.
Sohn says no one wants to sit down and discuss funding, so they,
“shove it under the rug. There aren’t people willing to bite the bullet
and figure out how to pay for things. You need money to take care of
things. But it’s difficult for politicians to say, ‘Increase taxes.’ We
have to go into savings first—how to save. In order to do that, we have
to have people in Washington willing to pay attention to it.”
Because, as a spokesperson for the NIH says, “It’s Congress that
appropriates the money. They give us our funding, and we’re grateful
for it.”
Other researchers are grateful for funding sources outside the U.S.
government. Just before the AAAS report was released this spring, the
Howard Hughes Medical Institute announced it would provide $600 million
to the “nation's most creative biomedical scientists” willing to
“tackle their most ambitious, risky research plans.”
Private biomedical research funding now constitutes more than 10
percent of the total money contributed to research, with the
pharmaceutical industry providing the most funding, and the U.S.
government providing about half as much as industry. In general, pharma
focuses on developing and testing new products, the government supports
basic research, and foundations generally fund some of what’s left over.
Historically, the government has provided funding for initial
investigations, and after a breakthrough, pharma translates the basic
science into medical applications and advanced technology. Advances in
understanding and treating AIDS and HIV are an example of this model.
But, says Woolley of Research!America, the system of government funding
leading to industry breakthroughs will collapse if public funding
doesn’t keep pace with opportunity. Speaking on Radio XM’s ReachMD talk
show last fall, she said, “We believe we’re going to see a flattening
or even a decrease in pharma funding for medical research that will
follow what we’ve seen at the NIH. The concern is that this slowing,
both through publicly funded and privately funded ways, really
compromises the robustness of the industry. Big pharma has a global
reach, but they depend on research conducted in the U.S.”
A lot seems to depend on research conducted in the United States.
Private industry and the U.S. government together provide 35 percent of
the world’s total research and development funding. Or they have.
According to Woolley, the percentage of investment is going down. “The
problem is people aren’t speaking out. Many members of the public as
well as health care professionals don’t even know where their elected
officials stand on key health-related issues, with the possible
exception of tort reform.”
According to Woolley, the most concerning declines in research are
in breast cancer clinical trials and Alzheimer’s disease. “Just at a
time when science opportunity is higher than ever,” she said, “we’ve
decided as a nation, via our elected officials, to freeze funding in
medical research at the NIH, at the CDC, at the NSF. It’s pretty much
across the board.”
Ironically, decreased funding comes at a time of rising health care
costs to individuals and with the knowledge that in 2002-03, the last
year of the large NIH budget increases, the number of people who died
from cancer decreased for the first time.
It’s not that there are no advocates in Congress for increasing
biomedical research funding. In fact, there are many. In Illinois,
Democratic Senators Barack Obama and Dick Durbin both advocate
increased investment in NIH. Their positions are outlined on the voter
education website, Your Candidates–Your Health 2008 (
www.yourcandidatesyourhealth.org). To date, Senator John McCain has declined to participate.
In the initiative, launched by Research!America, the Albert and Mary
Lasker Foundation and other partners, all members of Congress were
invited to complete a questionnaire telling Americans where they stand
on a range of research and other health-related issues. Members of the
public can take the same questionnaire and compare answers.
Once they’ve done that, individuals should contact their political
representatives. “Now is the time for advocacy,” Woolley says. “Members
of Congress will listen to their constituents. Remember, your voice
counts.”
Published: August 09, 2008
Issue: Fall 2008 Politics Issue